Adaptimmune Therapeutics plc (ADAP)

NASDAQ: ADAP · IEX Real-Time Price · USD
1.580
+0.060 (3.95%)
At close: Mar 27, 2024, 4:00 PM
1.600
+0.020 (1.27%)
Pre-market: Mar 28, 2024, 7:27 AM EDT

Company Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.

It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center.

Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Adaptimmune Therapeutics plc
Adaptimmune Therapeutics logo
Country United Kingdom
Founded 2008
IPO Date May 6, 2015
Industry Biotechnology
Sector Healthcare
Employees 449
CEO Adrian G. Rawcliffe

Contact Details

Address:
60 Jubilee Avenue, Milton Park
Abingdon, Oxfordshire, X0 OX14 4RX
United Kingdom
Phone 44 1235 430000
Website adaptimmune.com

Stock Details

Ticker Symbol ADAP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001621227
CUSIP Number 00653A107
ISIN Number US00653A1079
SIC Code 2836

Key Executives

Name Position
Adrian G. Rawcliffe Chief Executive Officer, Principal Accounting Officer and Director
Gavin Hilary James Wood ACA, BA (Hons) Chief Financial Officer
William C. Bertrand Jr., Esq., J.D. Chief Operating Officer
Dr. Elliot Norry B.A., M.D. Chief Medical Officer
Cintia Piccina Pharm.D. Chief Commercial Officer
Dr. Helen Katrina Tayton-Martin MBA, Ph.D. Co-Founder and Chief Business & Strategy Officer
Joanna Brewer Ph.D. Chief Scientific Officer
Dr. Juli P. Miller Ph.D. Vice President of Corporate Affairs and Investor Relations
Kerry Sharp Senior Vice President and General Council
Dana Lynch Senior Director of Corporate Communications

Latest SEC Filings

Date Type Title
Mar 26, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 6, 2024 10-K Annual Report
Mar 6, 2024 8-K Current Report
Feb 27, 2024 8-K Current Report
Feb 16, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024 8-K Current Report
Jan 30, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 29, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals